NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March
31, 2022
(unaudited)
NOTE
1 – ORGANIZATION AND LIQUIDITY
Organization
SRAX,
Inc. (“SRAX”, “we”, “us”, “our” or the “Company”) is a Delaware corporation
formed on August 2, 2011. SRAX is headquartered in Westlake Village, California but operates as a distributed virtual Company. As of
March 31, 2022, the unaudited Condensed Consolidated Financial Statements consist of SRAX and its wholly owned subsidiary LD Micro, Inc.
(“LD Micro”).
SRAX
is a technology firm focused on enhancing communications between public companies and their shareholders and investors. The Company currently
has one reportable and operating segment, which consists of one reporting unit consisting of two distinct business units:
| ● | The
unique SaaS platform, Sequire provides users many features which allow issuers to track their
shareholders’ behaviors and trends, then use data-driven insights to engage with shareholders
across marketing channels. |
| ● | Through
LD Micro, the Company organizes and hosts investor conferences within the micro and small-
cap markets, and plans to create several more niche events for the investor community. |
Each
of SRAX’s business units deliver valuable insights that assist the Company’s clients with their investor relations and communications
initiatives.
On
February 4, 2021, the Company acquired FPVD through a reverse acquisition involving BIGtoken, Inc. On December 29, 2021, the Company
deconsolidated the Company’s majority owned subsidiary BIG Token, Inc. (“BIGToken”) formerly known as Force
Protection Video Equipment Corporation (or “FPVD”). See Note 3 –Discontinued Operations.
Liquidity
and Capital Resources
The
Company has incurred significant losses since its inception and has not demonstrated an ability to generate cash in excess of its operating
expenses for a sustained period of time. As of March 31, 2022, the Company had cash and cash equivalents of $351,000 which is not sufficient
to fund the Company’s planned operations through one year after the date the unaudited Condensed Consolidated Financial Statements
are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one
year after the date that the unaudited Condensed Consolidated Financial Statements are issued.
The
unaudited Condensed Consolidated Financial Statements do not include any adjustments that might be necessary if the Company is unable
to continue as a going concern. Accordingly, the unaudited Condensed Consolidated Financial Statements have been prepared on a basis
that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities
and commitments in the ordinary course of business.
In
making this assessment, the Company performed a comprehensive analysis of current circumstances including: its financial position, cash
flow and cash usage forecasts, and obligations and debts. Although management has a long history of successful capital raises, the analysis
used to determine the Company’s ability as a going concern does not include cash sources outside the Company’s direct control
that management expects to be available within the next 12 months.
The
Company expects that its existing cash and cash equivalents, accounts receivable and marketable securities as of March 31, 2022, will
not be sufficient to enable it to fund the anticipated level of operations through one year from the date these financial statements
are issued. The Company projects the sale of its marketable security holding will represent a substantial portion of the cash required for operations for the foreseeable future. The Company’s sales of marketable securities are primarily through sale transactions that qualify for exemptions pursuant to Rule 144 of the Securities Act of 1933. The conditions required to be met to qualify for the exemptions under Rule 144 are often difficult to predict, making it difficult to predict the timing of the associated cash flows from the sales of these securities. The Company’s holdings of marketable securities are subject to risks and uncertainties such as fluctuations in pricing in the primary market, and legal restrictions that create uncertainty around realization and timing of cash flows.
The Company anticipates raising additional capital through the private and public sales of its equity or debt securities
and selling its marketable securities, or a combination thereof. Although management believes that such capital sources will be available,
there can be no assurances that financing will be available when needed in order to allow the Company to continue its operations, or
if available, on terms acceptable to it. If the Company does not raise sufficient capital in a timely manner, among other things, it
may be forced to scale back its operations or cease operations altogether.
Uncertainty
Due to Geopolitical Events
Due
to Russia’s invasion of Ukraine, which began in February 2022, and the resulting sanctions and other actions against
Russia and Belarus, there has been uncertainty and disruption in the global economy. Although the Russian war against
Ukraine did not have a material adverse impact on the Company’s revenue or other financial results for the three months
ended March 31, 2022, at this time the Company is unable to fully assess the aggregate impact the Russian war
against Ukraine will have on its business due to various uncertainties, which include, but are not limited to, the
duration of the war, the war’s effect on the economy, its impact to the businesses of the Company’s customers, and
actions that may be taken by governmental authorities related to the war.
COVID-19
Update
The
continuing COVID-19 global pandemic has caused significant disruption to the economy and financial markets globally, and the full extent
of the potential impacts of COVID-19 are not yet known. Circumstances caused by the COVID-19 pandemic are complex, and uncertain. The
impact of COVID-19 has not been significant to the Company’s results of operations, financial condition, and liquidity and capital
resources. Although no material impairment or other effects have been identified to date, there is substantial uncertainty in the nature
and degree of its continued effects over time. That uncertainty affects management’s accounting estimates and assumptions, which
could result in greater variability in a variety of areas that depend on these estimates and assumptions as additional events and information
become known. The Company will continue to consider the potential impact of the COVID-19 pandemic on its business operations.
NOTE
2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Presentation
The
accompanying Condensed Consolidated Financial Statements and notes thereto are unaudited. The unaudited interim Condensed Consolidated
Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”)
and pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). Certain information
and note disclosures normally included in the Company’s annual financial statements have been condensed or omitted. The December
31, 2021 Condensed Consolidated Balance Sheet was derived from financial statements but does not include all disclosures required by
GAAP. These interim unaudited Condensed Consolidated Financial Statements, in the opinion of management, reflect all normal recurring
adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim three-month
periods ended March 31, 2022 and 2021. The results for the three months ended March 31, 2022 are not necessarily indicative of the results
to be expected for the full year ending December 31, 2022 or for any future period.
These
unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial
Statements and the notes thereto for the year ended December 31, 2021, included in the Company’s annual report on Form 10-K filed
with the SEC.
Principles
of Consolidation
The
unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All material
intercompany transactions and balances have been eliminated in consolidation.
Use
of Estimates
The
unaudited Condensed Consolidated Financial Statements have been prepared in conformity with GAAP and require management of the Company
to make estimates and assumptions in the preparation of these unaudited Condensed Consolidated Financial Statements that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates and assumptions.
The
most significant areas that require management judgment and which are susceptible to possible change in the near term include, among
other items, the Company’s revenue recognition, valuation of marketable investment securities, stock-based compensation, income
taxes, purchase price for acquisitions, goodwill, other intangible assets, and the valuation of redemption features and other assets
and liabilities.
Fair
Value of Financial Instruments
The
accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair
value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal,
most advantageous market for the specific asset or liability.
In
determining fair value, the Company uses various valuation techniques. A fair value hierarchy for inputs is used in measuring fair value.
It maximizes observable inputs and minimizes unobservable inputs. Valuation techniques consistent with the market or income approach
are used to measure fair value. The fair value hierarchy is categorized into three levels:
| ● | Level
1 - Valuations based on unadjusted quoted prices in active markets for identical assets or
liabilities that the Company has the ability to access; |
| ● | Level
2 - Valuations based on inputs, other than quoted prices included in Level 1, that are observable
either directly or indirectly; and |
| ● | Level
3 - Valuations based on inputs that are unobservable and significant to the overall fair
value measurement. |
Fair
value is a market-based measure that is based on assumptions of prices and inputs considered from the perspective of a market participant
on the measurement date.
The
availability of valuation techniques and observable inputs can vary from investment to investment and are affected by a wide variety
of factors. The determination of fair value requires prudent judgment. Due to the inherent uncertainty of valuation, estimated values
may be materially different from values were a ready market available. Inputs used to measure fair value may fall into different levels
of the fair value hierarchy. In such cases, the item being valued is classified based on the hierarchy category of the lowest significant
level input to the fair value measurement. See Note 12 Fair Value of Financial Instruments.
Cash
and Cash Equivalents
The
Company considers all short-term highly liquid investments with a remaining maturity at the date of purchase of three months or less
to be cash equivalents. Cash and cash equivalents are recorded at cost, which approximates its fair value. The Company maintains its
cash and cash equivalents in banks insured by the Federal Deposit Insurance Corporation (“FDIC”) in accounts that at times
may be in excess of the federally insured limit of $250,000 per bank. The Company minimizes this risk by placing its cash deposits with
major financial institutions. As of March 31, 2022 and December 31, 2021, the Company had $101,000 and $1,098,000 in excess of the federal
insurance limit, respectively.
Marketable
Securities
Marketable
Securities consist of debt and equity securities. The Company accounts for marketable equity securities, including convertible preferred
shares at fair value pursuant to ASC 321 Investments – Equity Securities, and marketable debt securities at fair value in accordance
with ASC 320 – Investments Debt Securities. Marketable securities were approximately $28.8 million and $15.6 million as of March
31, 2022 and December 31, 2021, respectively.
Accounts
Receivable
Credit
is extended to customers based on an evaluation of their financial condition and other factors, and the Company usually does not require
collateral. Management periodically assesses the Company’s accounts receivable and, if necessary, establishes an allowance for
estimated uncollectible amounts. Accounts determined to be uncollectible are charged to operations when that determination is made. The
allowance for doubtful accounts was approximately $157,000 and $130,000 as of March 31, 2022 and December 31, 2021, respectively.
Concentration
of Credit and Significant Customer Risk
Financial
instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable.
Cash and cash equivalents are deposited with financial institutions within the United States. The balances maintained at these financial
institutions are generally more than the FDIC insurance limits. The Company has not experienced any loss on these accounts.
As
of March 31, 2022, the Company had 2 customers with an accounts receivable balance of approximately 43%. As of December 31, 2021, the
Company had one customer with an accounts receivable balance of approximately 11%. Additionally, included within accounts receivables,
the Company has a receivable of approximately $350,000 as of March 31, 2022 due from a prior subsidiary.
For
the three months ended March 31, 2022 and 2021, the Company had no customers that account for a significant percentage of total revenues.
Goodwill
and Intangible assets
Intangible
assets consist of (i) goodwill, intellectual property, trademarks, trade names and non-compete agreements acquired in business combinations
and capitalized software development costs. Other than goodwill and trademarks, intangible assets are stated at cost less accumulated
amortization. Amortization is provided for on the straight-line basis over the estimated useful lives of the assets of five years.
Impairment
of Goodwill, Intangible Assets and Other Long-lived Assets
Management
evaluates the recoverability of the Company’s definitive lived intangible assets and other long-lived assets when events or circumstances
indicate a potential impairment exists. Events and circumstances considered by the Company in determining whether the carrying value
of identifiable intangible assets and other long-lived assets may not be recoverable include, but are not limited to: significant changes
in performance relative to expected operating results; significant changes in the use of the assets; significant negative industry or
economic trends; a significant decline in the Company’s stock price for a sustained period of time; and changes in the Company’s
business strategy. In determining if impairment exists, the Company estimates the undiscounted cash flows to be generated from the use
and ultimate disposition of these assets. If impairment is indicated based on a comparison of the assets’ carrying values and the
undiscounted cash flows, the impairment loss is measured as the amount by which the carrying amount of the assets exceeds the fair value
of the assets.
Management
evaluates the recoverability of the Company’s goodwill annually at December 31 or more often as events or circumstances indicate
the fair value of a reporting unit is below its carrying value. The Company has determined that it operates as a single reporting unit for
the purposes of conducting this goodwill impairment assessment. If the fair value of a reporting unit is less than its carrying value,
an impairment loss is recorded to the extent that implied fair value of the goodwill within the reporting unit is less than its carrying
value.
No
impairments of goodwill or other long-lived assets have been recognized for the three months ended March 31, 2022 or 2021.
Revenue
Recognition
The
Company recognizes revenues upon the satisfaction of its performance obligation(s) (upon transfer of control of promised goods or services
to its customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services.
The Company determines the amount of revenue to be recognized through the application of the five-step process as follows:
| 1) | identification
of contracts with customers; |
| 2) | identification
of the distinct performance obligations in the contract; |
| 3) | determination
of the transaction price of the contract; |
| 4) | allocation
of transaction price among the performance obligations in the contract; and |
| 5) | recognition
of revenue as performance obligations are satisfied. |
The
Company has elected the following practical expedients allowed in accounting for its revenue recognition:
| ● | not
adjusting contract consideration for the effects of significant financing components if the
period between transfer or service and customer payment is expected to be less than one year; |
| ● | not
assessing performance obligations if they are immaterial in the context of the contract; |
| ● | excluding
sales and similar taxes from the transaction price; and |
| ● | not
disclosing the value of unsatisfied performance obligations for contracts with an original
expected length of one year or less. |
The
Company generates revenue primarily from its Sequire SaaS platform and its LD Micro subsidiary. Specifically, the Sequire SaaS platform
related revenue consists of (i) licensing subscriptions to access the platform, (ii) managed services involving data and marketing initiatives
and (iii) ancillary data supplementing the use of the platform. LD Micro revenues consist of attendee fees and event sponsorship fees
related investor conferences organized and hosted by the Company.
Sequire
SaaS platform
Sequire
SaaS platform agreements are typically for a period of 12-months and provide for monthly or annual payments in advance.
Many
of the Sequire SaaS platform agreements provide customers the ability to pay for the services with the issuance of the customers’
securities including common stock. The amount of consideration for these contracts is based on the estimated fair value of the underlying
securities on the contract date. See “Fair Value of Financial Instruments” for details over the calculation of fair value.
When
Sequire SaaS platform contracts contain multiple performance obligations, transaction consideration is allocated to each individual performance
obligation based on a relative Stand-Alone Selling Price (“SSP,”) basis. The Company determines SSP based on the price at
which the performance obligation would be sold separately.
Subscription
revenue is generally non-refundable regardless of the actual use and is recognized ratably over the non-cancellable contract term beginning
on the commencement date of each contract, which is the date the Company’s service is first made available to customers.
Managed
Services and Ancillary Data revenue is typically recognized using an output measure of progress by looking at the time elapsed as the
contracts generally provide the customer equal benefit throughout the contract period because the Company transfers control evenly by
providing a stand-ready service.
LD
Micro - Conference Revenue
LD
Micro agreements cover a specific event and provide for payment in advance or at the time of the event. Conference revenue from attendee
fees and sponsorship fees is recognized at the time of the event (i.e., at a point-in-time).
Contract
Receivables
Contracts
receivable represents amounts for which non-cancellable revenue contracts with customers have been finalized but the payment in the form
of securities issued by the customer have not been received by the Company.
Deferred
Revenue
Deferred
revenue resulting from amounts billed to, or cash received from, customers in advance of the Company satisfying its performance obligation
and recognizing the applicable revenue.
Preferred
stock
Preferred
stock liability represents amounts payable to holders of the Preferred Stock Series A shares upon the eventual liquidation of assets
designated for the sole purpose of paying dividends. Accordingly, the Company classified the Series A Preferred Shares as liability instruments
because in-substance, they represent a right to the payment of dividends upon the liquidation of specified assets, are automatically
returnable to the Company after the payments are made and feature no rights to further equity or residual interests in the Company.
Costs
to Obtain or Costs to Fulfill a Contract
The
Company has no costs that qualify as costs to obtain or costs to fulfill customer contracts.
Net
Income (Loss) Per Share
Basic earnings per share is calculated by
dividing net income by the weighted-average number of shares outstanding during the period. Diluted earnings per share is calculated by
dividing net income by the weighted-average number of common shares outstanding, after giving effect to all potentially dilutive common
shares outstanding during the period. Dilutive shares associated with options and warrants there were in the money were computed using the treasury stock
method and dilutive shares associated with convertible debt were computed using the if-converted method, which includes the effect of
excluding the convertible debenture interest expense from net income.
Securities that could potentially dilute basic net
income per share in the future that were not included in the computation of diluted net income per share were 1,770,885 and 11,867,520
during three months ended March 31, 2022 and March 31, 2021 respectively, because to do so would have been anti-dilutive
Basic and diluted earnings per share were calculated as follows:
SCHEDULE
OF BASIC AND DILUTED NET INCOME PER SHARE
| |
| | | |
| | |
| |
Three
months ended March 31, | |
| |
2022 | | |
2021 | |
| |
| | |
| |
Numerator: | |
| | | |
| | |
Net loss from discontinued operations | |
| - | | |
| (7,627,000 | ) |
Net income (loss) | |
| 3,728,000 | | |
| (11,944,000 | ) |
Less: Net loss attributable to non-controlling interest in discontinued operations | |
| - | | |
| 854,000 | |
Net income (loss) attributable to SRAX, Inc. | |
$ | 3,728,000 | | |
$ | (11,090,000 | ) |
| |
| | | |
| | |
Denominator: | |
| | | |
| | |
Weighted average common shares - basic | |
| 26,032,055 | | |
| 19,411,519 | |
Effect of dilutive securities | |
| | | |
| | |
Stock purchase warrants | |
| 1,690,655 | | |
| - | |
Convertible debentures | |
| 471,004 | | |
| - | |
Potentially dilutive common share equivalent | |
| 2,161,659 | | |
| - | |
Weighted average common shares - dilutive | |
| 28,193,714 | | |
| 19,411,519 | |
Recent
Accounting Pronouncements
In
June 2022, the FASB issued Accounting Standards Update (“ASU”) ASU 2022-03 Fair Value Measurements, which clarifies
the guidance in ASC 820 Fair Value Measurement (“ASC 820”), (1) when measuring the fair value of an equity security
subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3)
to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value
in accordance with ASC 820. The adoption did not impact the Company’s financial position, results of operations or cash flows.
Recent
Accounting Pronouncements Not Yet Adopted
In
August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06,
Debt-Debt with Conversion and Other Options which simplifies the accounting for convertible instruments by removing certain separation
models (including the cash conversion model and the beneficial conversion feature model) for convertible instruments. As a result, for
convertible instruments with conversion features that are not required to be accounted for as derivative instruments or that do not result
in substantial premiums accounted for as paid-in capital, the embedded conversion features are no longer separated from the host contract.
Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, and convertible
preferred stock will be accounted for as a single equity instrument measured at its historical cost as long as no other features require
bifurcation and recognition as derivatives. This guidance is effective on a modified retrospective or full retrospective basis for fiscal
years beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the
impact on the consolidated financial statements.
In
June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326) addressing accounting for credit
losses on financial instruments, which is designed to provide financial statement users with more information about the expected credit
losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. When determining
such expected credit losses, the guidance requires companies to apply a methodology that reflects expected credit losses and requires
consideration of a broader range of reasonable and supportable information to inform credit loss estimates. This guidance is effective
on a modified retrospective basis for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years.
The Company is currently evaluating the impact on the consolidated financial statements.
The
Company’s management reviewed all recently issued ASU’s not yet adopted by the Company and does not believe the future adoptions
of any such ASU’s may be expected to cause a material impact on the Company’s consolidated financial condition or the results
of its operations.
NOTE
3 –DISCONTINUED OPERATIONS
Background
On
February 4, 2021, the Company completed a share exchange agreement (“Exchange Agreement”) with FPVD. As part of the
Exchange Agreement the Company transferred all of the BIGToken assets and 100%
of the issued and outstanding shares of BIGToken for 149,562,566,534
shares of FPVD’s common stock and 5,000,000
shares of FPVD’s series A preferred stock. The Company accounted for the transaction as a reverse capitalization and resulted
in reducing the Company’s ownership in BIGToken from 100% to 88.9% and establishment of a non-controlling interest.
Subsequently, FPVD was renamed BIGToken.
Deconsolidation
On
December 29, 2021, BIGToken (formerly FPVD) completed a merger transaction with BritePool, Inc. (“BritePool”) (the “Merger”)
resulting in the Company’s ownership in BIGToken being reduced from 66% to approximately 4.99%. As a result of the Merger, BIGToken
issued 183,445,351,631 shares of its common stock (“Acquisition Shares”) for all of the issued and outstanding equity shares
of BritePool. On December 29, 2021, as a condition for the closing of the Merger, the Company exchanged 149,562,566,534 shares of BIGToken
common stock for 242,078 shares of BIGToken’s Series D Convertible Preferred Stock (“Series D Stock”) (the “Exchange”).
Simultaneously with the Exchange, the Company converted 22,162 shares of the Series D Stock into 13,692,304,136 shares of BIGToken’s
common stock, or approximately 4.99% of the issued and outstanding shares of BIGToken’s common stock.
Subsequent
to the transaction, the Company now owns 220,000 shares of BIGToken’s series D convertible, non-redeemable, non-voting preferred
stock and 13,692,304,136 shares of its common stock. As a result of the transaction, the Company no longer has a controlling financial
interest in BIGToken and deconsolidated BIGToken effective December 29, 2021, recognizing a loss
of $10.7 million as follows:
SCHEDULE
OF DECONSOLIDATION OF BUSINESS
Consideration | |
| | |
Fair value of Series D Stock and Common Stock | |
$ | 31,000 | |
Carrying amount of non-controlling interests of BIGToken | |
| 6,045,000 | |
Previous equity adjustments of non-controlling interest | |
| (12,510,000 | ) |
| |
| (6,434,000 | ) |
| |
| | |
Book basis of investment in BIGToken | |
| 4,250,000 | |
Loss on disposal of subsidiary | |
$ | (10,684,000 | ) |
The
Company determined the Series D Stock would be classified as a Level 3 asset as there is no observable market for quoted market price
for an identical asset. The Company engaged an independent third-party valuation expert to estimate the fair value of the Series D Stock.
The
financial results of BIGToken are presented as loss from discontinued operations, net of income taxes on the Company’s unaudited
Condensed Consolidated Statement of Operations for the three months ended March 31, 2021. The historical Condensed Consolidated Statement
of Cash Flows has also been revised to reflect the effect of the deconsolidation. The following table presents the financial results
of BIGToken:
SCHEDULE
OF ASSET AND LIABILITIES INCOME FROM DISCONTINUE OPERATIONS
| |
Three Months Ended
March 31, 2021 | |
Revenues | |
$ | 855,000 | |
| |
| | |
Cost and expenses | |
| | |
Cost of revenues | |
| 273,000 | |
Employee related costs | |
| 766,000 | |
Marketing and selling expenses | |
| 166,000 | |
Platform costs | |
| 86,000 | |
Depreciation and amortization | |
| 128,000 | |
General and administrative expenses | |
| 1,288,000 | |
Total cost and expenses | |
| 2,707,000 | |
Loss from operations | |
| (1,852,000 | ) |
| |
| | |
Other expense | |
| | |
Financing costs | |
| (5,775,000 | ) |
Total other expense | |
| (5,775,000 | ) |
| |
| | |
Loss from discontinued operations before income tax expense | |
| (7,627,000 | ) |
Income tax expense | |
| - | |
Loss from discontinued operations | |
$ | (7,627,000 | ) |
NOTE
4 – SALE AND PURCHASE OF ACCOUNTS RECEIVABLE
Sales
In
2020, the Company entered into certain financing agreements providing for the sale, with full recourse, of certain of its accounts receivable.
These transactions were accounted for as financing of accounts receivable and the related accounts receivable were not removed from the
Company’s consolidated balance sheet at the time of the transaction; rather, a liability was recorded for the proceeds received.
In 2020 subsequent to the transactions, the purchaser converted the payables into approximately $788,000 of the OID Convertible Notes
payable (“Debentures”) (See Note 8 - OID Convertible notes payable).
For
the year ended December 31, 2021, the Company entered into agreements with a third-party lender whereby it sold the Company’s right
to future subscription revenues of $625,000 for net proceeds of $576,000. Under the terms of the agreement, the Company may borrow funds
collateralized by the right to the revenues from Sequire platform contracts. The third-party lender receives a discount on the amount
sold and remits the net amount to the Company. The Company bears the risk of credit loss on the contracts. These transactions are accounted
for as secured borrowing arrangements and not as a sale of financial assets. During the three months ended March 31, 2022 the Company
entered into agreements with third party lenders to borrow against future receipts in the amount of $2,164,000. The Company received
net proceeds of $2,084,000, representing an aggregate OID of approximately 4%. These borrowings have terms of less than 12 months.
The
amount of borrowings outstanding was approximately $3,786,000 and $631,000 as of March 31, 2022 and December 31, 2021, respectively, and are included in other current liabilities
within our unaudited condensed consolidated balance sheets.
Purchase
Beginning
in the fourth quarter of 2021 and through March 31, 2022, the Company purchased certain accounts receivable from its formerly consolidated
subsidiary, BIGtoken providing for BIGtoken to sell, assign, transfer, convey and deliver to the Company all rights, title and interest
for its receivable aggregating $914,000 for a purchase price of $857,000, representing a 6% discount. As of March 31, 2022 and December
31, 2021, the outstanding receivable amounts to $352,000, which was included in accounts receivables and collected subsequent to March 31, 2022.
NOTE
5 – MARKETABLE SECURITIES
The
Company offers its customers the option to settle the contract price in the customer’s issued and publicly trading securities or
securities convertible into publicly traded securities (e.g., convertible debt), which could be in the form of common stock, preferred
stock or convertible debentures. The Company initially values the securities received at the fair market value on the date the contract
is executed, which value is used for revenue recognition purposes. After receipt of the securities, the securities are accounted for
as investments in debt and equity securities. The Company has concluded that all its debt securities should be classified as trading
securities based on its intent to sell them in the near term. Debt securities classified as trading securities and the equity securities
are measured at each reporting period at fair value with changes reported in earnings. Upon the sale of the securities, the Company recognizes
the final realized gain or (loss) in the consolidated statement of operations as a component of net income (loss).
The
following tables summarize the changes in the Company’s marketable securities during the three months ended March 31, 2022:
Three
months ended March 31, 2022:
SCHEDULE
OF MARKETABLE SECURITIES
| |
Total | | |
Common Stock | | |
Convertible Debentures | | |
Preferred Stock | | |
Warrants | |
Balances January 1, 2022 | |
$ | 15,617,000 | | |
$ | 10,735,000 | | |
$ | 4,187,000 | | |
$ | 599,000 | | |
$ | 96,000 | |
Additions | |
| 11,286,000 | | |
| 9,348,000 | | |
| 938,000 | | |
| 1,000,000 | | |
| - | |
Sales, at cost basis | |
| (2,330,000 | ) | |
| (2,330,000 | ) | |
| - | | |
| - | | |
| - | |
Realized Loss | |
| 1,053,000 | | |
| 1,053,000 | | |
| - | | |
| - | | |
| - | |
Designation for dividend distribution | |
| (10,790,000 | ) | |
| (10,577,000 | ) | |
| (213,000 | ) | |
| - | | |
| - | |
Change in fair value | |
| 3,198,000 | | |
| (108,000 | ) | |
| 3,251,000 | | |
| 151,000 | | |
| (96,000 | ) |
Balance March 31, 2022 | |
$ | 28,824,000 | | |
$ | 18,698,000 | | |
$ | 8,376,000 | | |
$ | 1,750,000 | | |
$ | - | |
The
Company’s sales of securities for the three months ended March 31, 2022, were approximately $1.3 million, with a book basis of
approximately $2.3 million which represented a loss of approximately $1 million, which the Company recorded as other income included
in the gains from marketable securities.
The
equity securities may be accounted for and classified into two categories and accounted for as follows:
| ● | Equity securities with a readily determinable fair value are reported at fair value, with unrealized gains and losses
included in earnings. The fair value of equity investments with fair values is primarily obtained from third-party pricing services. |
| ● | Equity securities without a readily determinable fair value are reported at their cost minus impairment, if any,
plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same
issuer and their impact on fair value. For equity investments without readily determinable fair values, when an orderly transaction for
the identical or similar investment of the same issuer is identified, the Company uses valuation techniques to evaluate the observed transaction(s)
and adjust the fair value of the equity investment. |
Concentration
Risk
The
Company’s holdings in marketable securities subject the Company to concentrations of market risks.
As
of March 31, 2022, the Company’s top six marketable security positions had an aggregate fair value of $13.1 million, which represented
45% of the Company’s holdings. Excluding marketability and liquidity discounts, these positions had an aggregate value of $14.9
million as of March 31, 2022. As of November 30, 2022 these positions have an aggregate value, excluding marketability and liquidity
discounts of $9.1 million, which represents a decrease of approximately 39% from March 31, 2022.
BIGtoken
Investment
On
February 15, 2022, the Company entered into a simple agreement for future equity (the “SAFE”) with its former BIGToken subsidiary.
Pursuant to the SAFE, the Company invested $1,000,000 in the SAFE. The amount funded into the SAFE at a given time is referred to herein
as the “SAFE Amount”. The Company is accounting for the SAFE as an equity investment carried at fair value with changes recorded
in earnings each period and is reflected as such in the above table.
Pursuant
to the terms of the SAFE, at any time that BIGtoken sells its securities (a “Financing”) prior to the termination of the
SAFE, the Company may, at its option, convert the SAFE into: (i) the number of shares of non-voting Series D Convertible Preferred Stock
(“Series D Preferred Stock”) equal to such (a) SAFE Amount divided by (b) the lowest price per share of equity securities
sold in any Financing (prior to the termination of the SAFE) multiplied by eighty percent (80%) (the “Conversion Price”)
and (ii) such number of warrants to purchase Series D Preferred Stock (the “Warrants”) equal to the SAFE Amount divided by
the Conversion Price. Upon issuance, the Warrants will (i) have a term of five (5) years, (ii) an exercise price equal to the Conversion
Price, and (iii) contain price protection provisions for subsequent financings.
NOTE
6 – DESIGNATED ASSETS FOR RETURN OF CAPITAL
On
August 17, 2021, the Company announced that it will be issuing a one-time dividend consisting of a share of Series A Preferred Stock
to shareholders, debenture holders, and certain warrant holders (“Recipients”) of record on September 20, 2021. The
Board of Directors designated certain of the Company’s marketable equity securities (“Designated Assets”) as of
September 20, 2021 to be used when liquidated, as a return of capital to the Recipients. See Note 9 - Series A Preferred Stock for
more details.
The
balance of designated assets consists of the following:
SCHEDULE OF DESIGNATED ASSETS
| |
March 31, 2022 | | |
December
31, 2021 | |
Cash | |
$ | 587,000 | | |
$ | 686,000 | |
Marketable equity securities | |
| 3,212,000 | | |
| 3,239,000 | |
Total | |
$ | 3,799,000 | | |
$ | 3,925,000 | |
The
activity in designated assets is as follows:
SCHEDULE
OF ACTIVITY IN DESIGNATED ASSETS
| |
Total | |
Balance as of December 31, 2021 | |
$ | 3,239,000 | |
Sales at cost | |
| (384,000 | ) |
Realized loss | |
| 116,000 | |
Change in fair value | |
| 241,000 | |
Balance as of March 31, 2022 | |
$ | 3,212,000 | |
The
Company’s sale of the designated marketable securities for the three months ended March 31, 2022, were approximately $268,000 with
a cost basis of approximately $384,000 which resulted in a realized loss of $116,000, which the Company recorded as other expense included
in the realized loss from designated assets.
NOTE
7 – NOTES RECEIVABLE
In
October 2020, the Company entered into unit redemption agreements with two counterparties providing for the counterparties to
repurchase from the Company units of the counterparty’s securities owned by the Company. Pursuant to the redemption
agreements, the counterparties repurchased the units for a combined repurchase price of $8
million with $7
million being paid on closing and the additional $1
million being deferred and due on the earlier of the three-year anniversary or upon sale of the counterparties. The Company had no
cost basis in the units and as a result the note receivable has no cost basis. The Company accounts for the note receivable as a
loan pursuant to ASC 310 – Loans . The $1
million in deferred payments was recorded with an implied discount of approximately $107,000,
which is being amortized over
3 years.
NOTE
8 – OID CONVERTIBLE NOTES PAYABLE
In
June 2020, the Company entered into a definitive securities purchase agreement (the “Securities Purchase Agreement or Transaction”)
with certain accredited and institutional investors (the “Purchasers”) for the purchase and sale of an aggregate of: (i)
$16,101,000 in principal amount of Original Issue Discount Senior Secured Convertible Debenture (the “Debentures”) for $14,169,000
(representing a 12% original issue discount) (“Purchase Price”) and (ii) warrants to purchase up to 6,440,561 shares of the
Company’s Class A common stock (the “Warrants”) in a private placement (the “Offering”). The Purchase Price
consisted of (a) $13,000,000 in cash and (b) the cancellation of $1,169,000 in outstanding debt. The Company received net proceeds of
approximately $9,100,000 after deducting the Placement Agent fees, the Debt Repayments and other offering expenses. The Company’s
obligations under the Debentures are secured by substantially all of the assets of the Company.
The
Debentures pay interest in cash at the rate of 12.0% per annum commencing on June 30, 2021, with such interest originally payable quarterly,
beginning on October 1, 2021. Commencing after the six-month anniversary of the issuance of the Debentures, the Company was required
to make amortization payments (“Amortization Payments”) with each Purchaser having the right to delay such Amortization Payments
by a six-month period up to three separate times (each, an “Extension”) in exchange for five percent (5%) in principal being
added to the balance of such applicable Debenture on each such Extension. The Debentures had an original maturity date of December 31,
2021 but were extended three times and now mature on June 30, 2023. Beginning on the date that the first Amortization Payment is due,
and on a monthly basis thereafter, the Company will be required to pay one hundred fifteen percent of the value of one-twelfth of the
outstanding principal plus any additional accrued interest due.
The
Debentures are convertible at the option of the holder into shares of the Company’s common stock at an initial conversion price
of $2.69 per share, subject to adjustment in the event of (i) stock splits and dividends, (ii) subsequent rights offerings, (iii) pro-rata
distributions, and (iv) certain fundamental transactions, including but not limited to the sale of the Company, business combinations,
and reorganizations.
In
the event a Purchaser converts a portion of its Debenture into shares of the Company’s Common Stock, such amount will be deducted
from the next applicable Amortization Payment. In the event such conversion exceeds the next applicable Amortization Payment, such excess
amount will be deducted, in reverse order, from future Amortization Payments.
Pursuant
to the terms of the Debentures and Warrants, a Purchaser will not have the right to convert any portion of the Debentures or exercise
any portion of the Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% or 9.99% (at the Purchaser’s
option) of the number of shares of Common Stock outstanding immediately after giving effect to such conversion or exercise, as such percentage
ownership is determined in accordance with the terms of the Debentures and the Warrants; provided that at the election of a holder and
notice to us such percentage ownership limitation may be increased to 9.99%; provided that any increase will not be effective until the
61st day after such notice is delivered from the holder to the Company.
Subject
to the Company’s compliance with certain conditions, upon ten trading days’ notice to the Purchasers, the Company has the
right to redeem the Debentures in cash at 115% of their outstanding principal, plus accrued interest. Additionally, in the event that
the Company (i) sells or reprices any securities (each, a “Redemption Financing”), or (ii) disposes of assets (except those
sold or transferred in the ordinary course of business) (each, an “Asset Sale”), then the Purchasers shall have the right
to (a) in the event of a Redemption Financing at a price per Common Stock equivalent of $2.50 or less per share, the Purchasers may mandate
that 100% of the proceeds be used to redeem the Debentures (b) in the event of a Redemption Financing at a price per Common Stock equivalent
of greater than $2.50 per share, the Purchasers may mandate that up to 50% of the proceeds be used to redeem the Debentures, and (c)
in the event of an Asset Sale, the Purchasers may mandate that up to 100% of the proceeds be used to redeem the Debentures.
The
Debentures also contain certain customary events of default provisions, including, but not limited to, payment default, breaches of covenants,
the occurrence of an event of default under certain material contracts of the Company, failure to register the shares underlying the
Debentures and Warrants, changes in control of the Company, delisting of its securities from its trading market, and the entering or
filing of certain monetary judgments against the Company. Upon the occurrence of any such event of default, the outstanding principal
amount of the Debenture plus liquidated damages, interest and other amounts owing in respect thereof through the date of acceleration,
shall become, at the Purchaser’s election, immediately due and payable in cash. The Company is also prohibited from certain activities
(unless waived by 67% of the then outstanding Purchasers, and including the lead Purchaser), including but not limited to, the creation
of certain debt obligations, liens on Company assets, amending its charter documents, repayment or repurchase of securities or certain
debt of the Company, or the payment of dividends.
The
Warrants are initially exercisable at $2.50 per share and, are subject to cashless exercise after six months if the shares underlying
the Warrants are not subject to an effective resale registration statement. The Warrants are also subject to adjustment in the event
of (i) stock splits and dividends, (ii) subsequent rights offerings, (iii) pro-rata distributions, and (iv) certain fundamental transactions,
including but not limited to the sale of the Company, business combinations, and reorganizations.
Pursuant
to a registration rights agreement (“Registration Rights Agreement”), the Company has agreed to file a registration statement
registering the resale of the shares of the common stock underlying the Debentures and the Warrants within forty-five days from the date
of the Registration Rights Agreement. The Company also agrees to have the registration statement declared effective within 90 days from
the date of the Registration Rights Agreement and keep the registration statement continuously effective until the earlier of (i) the
date after which all of the securities to be registered thereunder have been sold, or (ii) the date on which all the securities to be
registered thereunder may be sold without volume or manner-of-sale restrictions and without current public information pursuant to Rule
144 under the Securities Act. The Company is also obligated to pay the Investors, as partial liquidated damages, a fee of 2.0% of each
Purchaser’s subscription amount per month in cash upon the occurrence of certain events, including the Company’s failure
to file and/or have the registration statement declared effective within the time periods provided. As of March 31, 2022, the Company has continuously met its obligations under the Registration Rights Agreement.
Bradley
Woods & Co. Ltd. (“Placement Agent”) acted as the placement agent, in connection with the sale of the securities. Pursuant
to an engagement agreement, the Company agreed to pay the Placement Agent a cash commission of $1,040,000 and issue an aggregate of 478,854
Common Stock purchase warrants (“PA Warrants”). The PA Warrants are substantially similar to the Warrants, except that the
PA Warrants have an exercise price of $3.3625 per share. Additionally, upon the exercise of the Warrants issued in the Offering, the
Placement Agent will be entitled to eight percent (8%) of the cash proceeds received from such exercises. The fair value of the PA Warrants
at issuance was estimated to be $360,000.
The
Company first allocated the cash proceeds to the loan and the equity classified warrants on a relative fair value basis, secondly, the
proceeds were allocated to the beneficial conversion feature. The proceeds allocated to the warrants and the beneficial conversion feature
resulted in a debt discount being amortized as additional interest expense using the effective interest method over the term.
The
table below summarizes the Debenture related activity during the three months ended March 31, 2022:
SCHEDULE OF OID CONVERTIBLE DEBENTURES
| |
Principal | | |
Debt
discount | | |
Net book
value | |
Balances January 1, 2022 | |
$ | 1,267,000 | | |
$ | (103,000 | ) | |
$ | 1,164,000 | |
Extension | |
| | | |
| | | |
| | |
Conversion | |
| | | |
| | | |
| | |
Amortization | |
| - | | |
| 17,000 | | |
| 17,000 | |
Balance March 31, 2022 | |
$ | 1,267,000 | | |
$ | (86,000 | ) | |
$ | 1,181,000 | |
As
of March 31, 2022 and December 31, 2021, the Company has classified the debt as current liability because management intends to redeem
the remaining convertible debentures within the following 12 months.
NOTE
9 – COMMON AND PREFERRED STOCK
Common
Stock
The
Company’s certificate of incorporation provides for two classes of common stock: Class A common stock (authorized 250,000,000 shares,
par value $0.001), which has one vote per share, and Class B common stock (authorized 9,000,000 shares, par value $0.001), which has
ten votes per share. Any holder of Class B common stock may convert his or her shares at any time into shares of Class A common stock
on a share-for-share basis. Otherwise, the rights of the two classes of common stock are identical.
In
August 2021, the Board of Directors approved a share repurchase program pursuant to which the Company is authorized to repurchase up
to $10,000,000 of Class A Common Stock in privately negotiated transactions or in the open market at prices per share not exceeding the
then-current market prices. Under the program, management has discretion to determine the dollar amount of shares to be repurchased and
the timing of any repurchases in compliance with applicable law and regulation. This includes purchases pursuant to Rule 10b5-1 plans,
including accelerated share repurchases. The program does not have an expiration date.
During
the year ended December 31, 2021, the Company repurchased 155,000 shares of Common Stock, for an aggregate purchase price of $793,000
pursuant to the Company’s Share Buy-Back program. The shares were retired as of December 31, 2021. No amounts were repurchased
in the three months ended March 31, 2022. The total remaining authorization for future common share repurchases under the Company’s
share repurchase program was $9.2 million as of March 31, 2022.
During
the year ended December 31, 2021, the Company sold 53,616 shares of common stock, resulting in proceeds of approximately $284,000, through
sales under its At the Market (ATM) offering.
Preferred
Stock
The
Company is authorized to issue 50,000,000 of preferred stock, par value $0.001, of which 36,462,417 shares are designated as Series A
Preferred Stock (“Dividend Shares”). The Company’s Board of Directors, without further stockholder approval, may issue
preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences,
qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different
series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights,
redemption provisions, sinking fund provisions and other matters. The Board of Directors may authorize the issuance of preferred stock,
which ranks senior to the Company’s common stock for the payment of dividends and the distribution of assets on liquidation. In
addition, the Board of Directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of the Company’s
common stock to be effective while any shares of preferred stock are outstanding.
On
September 20, 2021, the Company filed a certificate of designation (the “COD”) of preferences, rights, and limitations of
Series A Non-Voting Preferred Stock (“Series A Preferred Stock”) with the Secretary of State of Delaware. Pursuant to the
COD, the Company is authorized to issue up to 36,462,417 shares of Series A Preferred Stock (the “Dividend Shares”).
On
September 27, 2021, the Company issued a one-time dividend of 36,462,417 shares of series A preferred stock (“Preferred Stock”)
to certain Qualified Recipients (the “Dividend”) which is convertible into shares of common stock on a 1 for 1 basis. The
preferred stock entitles the Qualified Recipients with the right to receive the net proceeds from sales of certain marketable securities
that the Company received through its Sequire Platform services. See Note 6 – Designated Assets for Return of Capital.
As
of the Record Date, the following holders of securities were entitled to receive the Dividend (collectively, the “Qualified Recipients):
| i. | each
outstanding share of Class A common stock (the “Common Stock”), of which 25,160,504
shares were issued and outstanding, |
| ii. | each
share of Common Stock underlying outstanding common stock purchase warrants containing a
contractual right to receive the Dividend (“Warrants”) of which, 10,327,645 were
outstanding, and |
| iii. | each
original issue discount senior convertible debenture (the “Debentures”) issued
on June 30, 2021, containing a contractual right to receive the Dividend on an as converted
to Common Stock basis, of which $2,486,275 of Debentures were outstanding in principal and
interest, convertible into 974,268 shares of Common Stock. |
The Company’s management has evaluated the Preferred Stock and determined that Preferred Stock is mandatorily
redeemable upon the distribution of the net proceeds from the sale of the designated marketable securities. Accordingly, it is classified
as a liability recorded at fair value, with changes in fair value being reflected in earnings.
NOTE
10 – EQUITY COMPENSATION PLANS AND WARRANTS
Equity
Compensation Plans
As
of March 31, 2022, the Company has approximately 228,000 shares of Class A Common Stock reserved for issuance under the Company’s
equity compensation plans.
In
the three months ended March 31, 2022, the Company issued the below shares and granted the following stock-based awards:
On January 2, 2022, Michael Malone, our Chief Financial Officer exercised an option to purchase 100,000 shares of our common stock that was issued on December 15, 2018. The option was exercised on a cashless basis and included 57,016 shares withheld pursuant to the cashless exercise and an additional 16,732 shares withheld for tax withholding. Accordingly, we issued Mr. Malone 26,252 shares of common stock.
On January 3, 2022, we issued four (4) common stock purchase options to our non-employee directors, pursuant to our amended non-employee director compensation policy. Each option entitled the holder to purchase 29,533 shares of common stock at an exercise price of $4.35 per share, for an aggregate exercise amount of $128,500. The options vest in equal quarterly over a one (1) year period from the issuance date. The options expire on the seven (7) year anniversary of the issuance date. Each option has a Black-Scholes value of $100,000.
During the month of January 2022, non-executive employees exercised a total of 227,667 stock options. These options were exercised on a cashless basis, and included 161,938 shares withheld pursuant to cashless exercise and tax withholdings. This resulted in the issuance of 65,729 shares of common stock.
On
January 6, 2022, we issued non-executive employees, options to purchase 380,000 shares of Class A common stock. The option has an exercise
price of $4.25 per share, a term of five (5) years and vests in equal quarterly installments over a three (3) year period from the grant
date. The option had a Black-Scholes value on the grant date of $1,153,000.
On January 6, 2022, we issued Christopher Miglino, our Chief Executive Officer, an option to purchase 120,000 shares of common stock. The option has an exercise price of $4.25 per share, a term of seven (7) years and vests in equal quarterly installments over a three (3) year period from the grant date. The option had a Black-Scholes value on the grant date of $397,000.
On
January 6, 2022, we issued an employee an option to purchase 100,000 shares of common stock. The option has an exercise price of $4.25
per share, a term of seven (7) years and vests in equal quarterly installments over a three (3) year period from the grant date. The
option had a Black-Scholes value on the grant date of $331,000.
On January 6, 2022, we issued Michael Malone, our Chief Financial Officer, a conditional option to purchase 100,000 shares of Class A common stock. The option is a conditional grant, subject to shareholder approval. Assuming approval by the shareholders, the option has an exercise price of $4.25 per share, a term of seven (7) years and vests in equal quarterly installments over a three (3) year period from the grant date. The option had a Black-Scholes value on the grant date of $331,000.
On
January 6, 2022, we issued an employee an option to purchase an aggregate of 20,000
shares of common stock. The option is a conditional
grant, subject to shareholder approval. The option has an exercise price of $4.25
per share, a term of five (5)
years, and vest in equal quarterly installments over a three (3)
year period from the grant date. The option had a Black-Scholes value on the grant date of $61,000.
The
per-share fair value of each stock option with service conditions only granted during the quarter ended March 31, 2022 was determined on the grant date using the Black-Scholes
option pricing model with the following assumptions:
SCHEDULE OF FAIR VALUE
STOCK OPTION ASSUMPTIONS
| |
Grant date | |
| |
1/3/2022 | | |
1/6/2022 | | |
1/6/2022 | |
Expected term (in years) | |
| 5.0 | | |
| 5.0 | | |
| 4.0 | |
Risk-free interest rate | |
| 1.55 | % | |
| 1.55 | % | |
| 1.60 | % |
Expected volatility | |
| 90.0 | % | |
| 90.0 | % | |
| 90.0 | % |
Expected dividend yield | |
| - | % | |
| - | % | |
| - | % |
The
following table details provides a summary of the Company’s stock option activity for the three months ended March 31, 2022:
SCHEDULE
OF STOCK OPTION ACTIVITY
| |
Option
Shares | | |
Weighted
Average
Exercise
Price | | |
Weighted
Average
Remaining
Term (years) | | |
Aggregate
Intrinsic
Value | |
Outstanding December 31, 2021 | |
| 1,334,287 | | |
$ | 3.02 | | |
| 2.4 | | |
$ | 3,096,176 | |
Granted | |
| 718,132 | | |
$ | 4.27 | | |
| 5.7 | | |
$ | 404,703 | |
Exercised | |
| (327,667 | ) | |
$ | 3.15 | | |
| | | |
$ | 549,931 | |
Forfeited | |
| (60,000 | ) | |
$ | 3.42 | | |
| | | |
| | |
Outstanding March 31, 2022 | |
| 1,664,752 | | |
$ | 3.52 | | |
| 4.2 | | |
$ | 2,193,289 | |
| |
| | | |
| | | |
| | | |
| | |
Exercisable at March 31, 2022 | |
| 654,281 | | |
$ | 3.05 | | |
| 2.9 | | |
$ | 1,174,649 | |
The
Company did not issue any stock-based awards in the three months ended March 31, 2021.
During
the three months ended March 31, 2022 and 2021, the Company recorded stock-based compensation expense of $358,000 and $253,000, respectively
with such costs being included in Employee related costs on our unaudited Condensed Consolidated Statements of Operations. At March 31,
2022, there was $2,572,000 of unrecognized compensation expense expected to be recognized over the next 2.75 years on average.
Warrants
During
the three months ended March 31, 2022, the Company did not have any activity with warrants.
On
February 21, 2021 the Company entered into an agreement with the Debenture holders to exercise 4,544,440 of the Warrants. In consideration
for the Debenture holders to exercise the Warrants, the Debenture holders would receive a new registered warrant (“New Warrant”)
to purchase an aggregate of 4,545,440 shares of the Company’s common stock at an exercise price of $7.50 per share expiring on
January 31, 2022. Each investor agreed to pay $0.125 for each New Warrant. The net proceeds received of approximately $11,022,000 consisted
of the exercise price of $11,363,000, $568,000 for the purchase of the New Warrant less solicitation fees of approximately $909,000.
The
New Warrants were valued using the Black Scholes option pricing model at a total of $7,737,000 based on a one-year term, implied volatility
of 96%, a risk-free equivalent yield of 11%, and stock price of $5.83. The fair value of the New Warrants was expensed and included in
Financing Costs for the three months ended March 31, 2021.
Additionally
during the three months ended March 31, 2021, there were an additional 28,566 warrants exercised.
During
the three months ended March 31, 2021, other warrant holders exercised warrants to purchase 399,880 shares for approximately $1,200,000.
At
March 31, 2022, the Company had the following outstanding and exercisable warrants:
SUMMARY
OF OUTSTANDING AND EXERCISABLE WARRANTS
Warrant
Shares | | |
Weighted
Average
Exercise
Price | | |
Maturity
Date | |
| 2,651,246 | | |
$ | 3.61 | | |
| 2022 | |
| 2,440,359 | | |
$ | 2.73 | | |
| 2023 | |
| 95,549 | | |
$ | 4.91 | | |
| 2024 | |
| 5,187,154 | | |
$ | 3.22 | | |
| | |
NOTE
11 – REVENUE
The
Company has two business units, one operating segment, one reportable segment and one reporting unit. The Sequire segment includes the
licensing of the Company’s proprietary SaaS platform and associated data analysis technologies, consumer and investor targeted
marketing solutions to allow users of the Company’s SaaS platform to act on the insights obtained through the Company’s technologies,
and LD Micro, which is in the business of hosting events and conference for microcap public companies.
The
following table summarizes revenue by revenue stream for the three months ended March 31:
SCHEDULE
OF REVENUE BY REVENUE STREAM
| |
2022 | | |
2021 | |
Sequire platform revenue | |
$ | 7,499,000 | | |
$ | 4,508,000 | |
Conference revenue | |
| - | | |
| 45,000 | |
Other revenue | |
| - | | |
| 364,000 | |
Total revenue | |
$ | 7,499,000 | | |
$ | 4,917,000 | |
The
following table summarizes revenue recognized in exchange for customer securities and cash for the three months ended March 31:
SCHEDULE
OF REVENUE RECOGNIZED IN EXCHANGE FOR CUSTOMER SECURITIES AND CASH
| |
2022 | | |
2021 | |
Customer securities | |
$ | 6,444,000 | | |
$ | 3,471,000 | |
Cash | |
| 1,055,000 | | |
| 1,466,000 | |
Total revenue | |
$ | 7,499,000 | | |
$ | 4,917,000 | |
As
of March 31, 2022 and December 31, 2021, contract liabilities representing deferred revenue were approximately $16.7 million and $12.9
million, respectively. Revenue recognized from the balances of deferred revenue was $6.4 million and $3.5 million for the three months
ended March 31, 2022 and 2021, respectively.
As
of March 31, 2022 and December 31, 2021, contracts receivable amounted to $1,460,000 and $844,000, respectively.
NOTE
12 – FAIR VALUE OF FINANCIAL INSTRUMENTS
The
carrying amounts of certain financial instruments, including cash and cash equivalents and accounts payable and accrued expenses, approximate
their respective fair values due to the short-term nature of such instruments.
The
carrying amount of our debt and notes receivable approximate their fair value.
Valuation
of Marketable Securities
An
integral part of the Company’s fair value measurement process is the assessment of the type of securities as well as the securities’
liquidity and marketability. Warrants are initially valued at cost, if acquired for cash, or at intrinsic value. Convertible debt is
valued based on an analysis of the implied call option and a discounted cash flow analysis of the debt component. Equity securities are
valued using the quoted prices times the number of shares acquired. The securities are then evaluated based on their marketability (usually
based on the restrictions on resale into the securities primary market) and liquidity.
Investments
in restricted securities of public companies cannot be offered for sale to the public until the company complies with certain statutory
requirements. Investments in restricted securities of public companies are generally categorized in Level 2 of the fair value hierarchy.
However, investments in public companies may be categorized in Level 3 of the fair value hierarchy depending on the level of observable
liquidity. Specifically, if the Company determines the market activity is not sufficient to conclude the market activity represents an
Active Market.
Assets
and Liabilities Measured at Fair Value on a Recurring Basis
The
Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate
level in which to classify them for each reporting period. This determination requires significant judgments to be made. The Company
considers marketable securities without sufficient liquidity to sell within 6 months of the date of acquisition and securities that will
not be eligible for resale in the public markets through Rule 144 for 1 year from the date acquisition to be valued with Level 2 inputs.
The
contract assets represent a forward contractual right to receive securities pursuant to a revenue contract. As of March 31, 2022 and
December 31, 2021, the Company determined the value of the securities underlying the contract asset to have a fair value of $1,460,000
and $844,000,
respectively. Contract assets within level 3 at December 31, 2021 were received during the three months ended March 31, 2022, and
are now included within marketable securities. Contract assets as of March 31, 2022 relate to new contracts for which securities have
not been received.
The
Company had the following financial assets at March 31, 2022 and December 31, 2021:
SCHEDULE OF ASSETS MEASURED AT FAIR VALUE
| |
Balance as of
March 31,
2022 | | |
Quoted Price in
Active Markets
for Identical
Assets
(Level 1) | | |
Significant
Other
Observable
Inputs
(Level 2) | | |
Significant
Unobservable
Inputs
(Level 3) | |
Assets: | |
| | | |
| | | |
| | | |
| | |
Marketable securities | |
$ | 28,824,000 | | |
$ | 6,715,000 | | |
$ | 9,277,000 | | |
$ | 12,832,000 | |
Designated assets marketable securities | |
| 3,212,000 | | |
| 2,390,000 | | |
| 822,000 | | |
| - | |
Contract assets | |
| 1,460,000 | | |
| 892,000 | | |
| 568,000 | | |
| - | |
Total Assets | |
$ | 33,496,000 | | |
$ | 9,997,000 | | |
$ | 10,667,000 | | |
$ | 12,832,000 | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Series A Preferred Stock | |
$ | 3,799,000 | | |
$ | - | | |
$ | 3,799,000 | | |
$ | - | |
Total liabilities | |
$ | 3,799,000 | | |
$ | - | | |
$ | 3,799,000 | | |
$ | - | |
| |
Balance as of
December 31,
2021 | | |
Quoted Price in
Active Markets
for Identical
Assets
(Level 1) | | |
Significant
Other
Observable
Inputs
(Level 2) | | |
Significant
Unobservable
Inputs
(Level 3) | |
Assets: | |
| | | |
| | | |
| | | |
| | |
Marketable securities | |
$ | 15,617,000 | | |
$ | 6,134,000 | | |
$ | 2,448,000 | | |
$ | 7,035,000 | |
Designated assets marketable securities | |
| 3,925,000 | | |
| 259,000 | | |
| 3,666,000 | | |
| - | |
Contract assets | |
| 844,000 | | |
| - | | |
| - | | |
| 844,000 | |
Total assets | |
$ | 20,386,000 | | |
$ | 6,393,000 | | |
$ | 6,114,000 | | |
$ | 7,879,000 | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Series A Preferred Stock | |
$ | 3,925,000 | | |
$ | - | | |
$ | 3,925,000 | | |
$ | - | |
Total liabilities | |
$ | 3,925,000 | | |
$ | - | | |
$ | 3,925,000 | | |
$ | - | |
Changes
in Level 3 assets measured at fair value
The
following table presents additional information about Level 3 assets measured at fair value. Both observable and unobservable inputs
may be used to determine the fair value of assets classified within the Level 3 category. As a result, the unrealized gains and losses
for the assets and liabilities within the Level 3 category may include changes in fair value that were attributable to both observable
and unobservable inputs. Transfers to/from Levels 1, 2 and 3 are recognized at the beginning of the reporting period in which a change
in valuation technique or methodology occurs. Changes in Level 3 assets measured at fair value the three months ended March 31, 2022,
were as follows:
SCHEDULE
OF FAIR VALUE AT ASSETS
| |
Balance at January 1,
2022 | | |
Acquisitions | | |
Sales and dispositions | | |
Transfers into
Level 3 | | |
Transfers out of Level 3 | | |
Realized & unrealized gains
(losses) | | |
Balance March 31,
2022 | |
Common stock | |
$ | 2,154,000 | | |
$ | 481,000 | | |
$ | (14,000 | ) | |
$ | - | | |
$ | - | | |
$ | 85,000 | | |
$ | 2,706,000 | |
Convertible debt | |
| 4,186,000 | | |
| 938,000 | | |
| - | | |
| - | | |
| - | | |
| 3,252,000 | | |
| 8,376,000 | |
Warrants | |
| 96,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (96,000 | ) | |
| - | |
Preferred stock | |
| 599,000 | | |
| 1,000,000 | | |
| - | | |
| - | | |
| - | | |
| 151,000 | | |
| 1,750,000 | |
Total Investments | |
$ | 7,035,000 | | |
$ | 2,419,000 | | |
$ | (14,000 | ) | |
$ | - | | |
$ | - | | |
$ | 3,392,000 | | |
$ | 12,832,000 | |
The
Company had no Level 3 assets or liabilities in the three months ended March 31, 2021.
Valuation
processes for Level 2 and 3 Fair Value Measurements
Fair
value measurement of certain of our marketable securities fall within Level 2 and 3 of the fair value hierarchy. The fair value measurements
are evaluated by management to ensure that changes are consistent with expectations of management based upon the sensitivity and nature
of the inputs.
The
Company classifies certain assets as Level 3 assets if the estimated fair value was derived from level 3 inputs. The Company utilizes
a put option pricing model to arrive at a discount for lack of marketability and liquidity associated with restrictions on sales into
the public market. The Company generally classifies restricted securities in public companies as level 2, however in circumstances where
the observed level of liquidity is low and the quoted market price is deemed unreliable they may be categorized in Level 3 of the fair
value hierarchy. The Company considers marketable securities without sufficient liquidity to sell within 6 months of the date of acquisition
and securities that will not be eligible for resale in the public markets through Rule 144 for 1 year from the date acquisition to be
valued with Level 2 inputs.
The
fair value of the Company’s Series A Preferred Stock may change significantly, impacting the Company’s assumptions used to
estimate its fair value. The valuation of the Series A Preferred Stock is primarily based on the valuation of its underlying marketable
securities. The marketable securities that are underlying the Series A Preferred Stock are classified as Designated Assets on the Company’s
balance sheet and include Level 1 and Level 2 marketable securities and cash.
The
following table lists the significant unobservable inputs used to value assets classified as Level 3 of March 31, 2022. The table is
not intended to be all-inclusive, but instead identifies the significant unobservable inputs relevant to the determination of fair values.
The other Level 3 assets have been valued using unadjusted third-party transactions and, unadjusted historical third-party information,
or the unadjusted net asset values of the securities’ issuer. No unobservable inputs internally developed by the Company have been
applied to these assets, and therefore are omitted from the following table.
SCHEDULE
OF FAIR VALUE ASSETS SIGNIFICANT UNOBSERVABLE INPUTS
Assets | |
Valuation Technique | |
Unobservable inputs | |
Range | |
Common stocks | |
Put option pricing model | |
Discount for lack of marketability | |
| 0% - 32.3% | |
| |
| |
| |
| | |
Convertible preferred stock | |
Put option pricing model | |
Discount for lack of marketability | |
| 0%
- 54% | |
| |
| |
| |
| | |
Convertible debt | |
Discounted cash flow | |
Maturity | |
| 0 - 35 months | |
| |
| |
Risk adjusted discount factor | |
| 14.34% | |
| |
Option pricing model | |
Volatility | |
| 52%
- 151%
| |
| |
| |
Risk-free interest rate | |
| 1.02% - 1.55% | |
| |
| |
Dividend yield | |
| 0% | |
| |
| |
Time to maturity | |
| 0
- 35 months | |
Sensitivity
of Level 3 measurements to changes in significant unobservable inputs
The
process of estimating the fair value of securities without active markets involves significant estimates and judgement on behalf of management.
These estimated fair values may not be realized in a current sale or immediate settlement of the asset or liability. Additionally, there
are inherent uncertainties in any fair value measurement techniques, and changes in the underlying assumptions used could significantly
affect the fair value measurement amounts.
Changes
in each of these significant unobservable valuation inputs will impact the fair value measurement of the financial instrument generally
as follows:
|
● |
An increase or decrease in the volatility of the common stock that underlies our holdings in convertible debt would result in a directionally
similar change in the estimated fair value. |
|
|
|
|
● |
An increase or decrease in the risk-free interest rate or risk adjusted discount factor would result in an inverse change in the estimated
fair value of our convertible debt. |
|
|
|
|
● |
An increase in the dividend yield would increase the estimated value of the convertible debt. |
|
|
|
|
● |
A change in the maturity may result in either an increase or decrease in estimated fair value of the convertible debt. |
|
|
|
|
● |
An increase or decrease in the discount for lack of marketability of our common stock holdings and the common stock that underlies our
preferred stock would generally result in an inverse change in the estimated fair value. |
Instruments
for which unobservable inputs are significant to their fair value measurement (i.e., Level 3) include securities in which we deem their
market to be inactive or unreliable. The Company reviews and updates the fair value hierarchy classifications on a quarterly basis. Changes
from one quarter to the next that are related to the observable inputs to a fair value measurement may result in a reclassification from
one hierarchy level to another.
NOTE
13 – RELATED PARTY TRANSACTIONS
The
Company has entered into an agreement providing access to a suite at the Sofi Stadium in Los Angeles from an entity wholly owned by Christopher
Miglino, our CEO. The agreement entitles the Company to game tickets, optional tickets for other stadium events, and suite and conference
room access during business days. In May of 2022, the Company renewed the agreement for four (4) additional National Football League
seasons for an average rate per year of approximately $497,000. The amount charged to the Company is a pass-through of the actual expenses
charged by the stadium to the related party, without markup. The agreement terminates in February 2026.
NOTE
14 – SUBSEQUENT EVENTS
Common stock issue for Warrants
Subsequent to March 31, 2022, the Company issued approximately 196,000 shares
of the Company’s common stock for the exercise of warrants.
CVR
Agreement
On
June 13, 2022, the Company entered into an agreement with an institutional investor whereby in exchange for the payment of $405,000 (the
“Purchase Price”), the investor received (i) the right to receive the net proceeds upon the sale of certain marketable securities
held by the Company (“CVR Payments”) with a quoted price equal to $674,000 (with a guaranteed minimum return of 120% of such
Purchase Price and (ii) the right after 90 days but before 120 days to demand payment of 120% of the Purchase Price in cash less amounts
previously paid from the CVR Payments.
Extension
of Outstanding Original Issue Discount Senior Secured Convertible Debentures
On
July 1, 2022, the holders (“Holders”) of $1,102,682 in principal of the Company’s Original Issue Discount Senior Secured
Convertible Debentures (“Debentures”), representing all of the outstanding Debentures that were originally issued on June
30, 2020, entered into an agreement with the Company to (i) extend the maturity date of the Debentures until December 31, 2023 and (ii)
extend the first date that monthly redemptions are required to be made by the Company to begin on January 1, 2023 (the “Debenture
Extension”). As consideration for the Debenture Extension, the Company increased the principal amount outstanding on the Debentures
by five percent (5%). Additionally, the holders of the Debentures have the unilateral right to extend the maturity date and monthly redemption
period by an additional six (6) month period at any time prior to January 1, 2023 for an additional five percent (5%) to be added to
the outstanding principal of such Debentures. The Debentures, including the additional principal added to the Debentures are secured
by substantially all of the assets of the Company pursuant to a security agreement entered into between the Company and Holders contemporaneous
with the original issuance of the Debentures (the “Security Agreement”).
Bridge
Note
On
July 1, 2022, the Company issued an original issue discount bridge note in principal amount of $650,000 (“Bridge Note”) to
an institutional investor in exchange for $500,000 in cash. The bridge note was non-interest bearing and had a maturity date of August
15, 2022. The Company’s obligations pursuant to the bridge note were secured by substantially all of the assets of the Company
pursuant to the terms of the Security Agreement.
On
August 8, 2022, as described below, the Bridge Note was exchanged for a revolving note in the Senior Secured Revolving Credit Facility.
Senior
Secured Revolving Credit Facility
On
August 8, 2022, the Company entered into a senior secured revolving credit facility agreement with an institutional investor to initially
borrow up to $9,450,000 in the aggregate from time to time (each a “Revolving Loan”). The loan maximum amount accessible
is limited to $5.5 million until the Company is current with its reporting obligations. The loan is secured by all the assets of the
Company and is guaranteed by the Company’s wholly owned subsidiary, LD Micro, Inc. As part of the transaction, the Company also
amended and restated lender’s outstanding warrants to extend the maturity date of a total of 2,590,358 Common Stock purchase warrants
until September 30, 2023.
On
closing, the lender advanced $5,580,000 consisting of $4,930,000 in cash and the exchange of the existing outstanding $650,000 bridge
note. Upon the Company meeting certain conditions, the Lender will advance up to an additional $3,870,000.
The
principal balance of each Revolving Loan will reflect an original issue discount of ten percent (10%); provided that beginning on the
date that is twelve (12) months from the Effective Date, such original issue discount will increase to twelve percent (12%) in the event
the Prime borrowing rate increases to 6.75%. The Revolving Loans have a maturity date of the earlier of (i) twenty-four (24) months from
the Effective Date or (ii) the occurrence of an event of default, as described in the Loan Documents.
Commencing
on the first day of each month after the Effective Date, the outstanding balance of the Revolving Loan will be paid as calculated based
on a percentage of the Company’s collections from the sale of certain of its marketable securities.
The
Revolving Note is initially convertible into shares of Common Stock at a conversion price of $15.00 per share (“Conversion Price”).
The Conversion Price is subject to adjustment in the event of stock splits, dividends, fundamental transactions and certain future sales
of the Company’s Common Stock.
As
consideration for Lender entering into the Loan Documents, Lender will be entitled to receive, in addition to any payment made under
the Credit Agreement, 10% of the net proceeds received by the Company from the sales of securities received during the term of the Revolving
Loan.
For
the Company to enter into the Credit Agreement, we were required to issue 32,000 shares of the Company’s common stock as a breakup
fee to an unrelated lender as a result of a failed offering.
Extension
of Warrants
As
part of the transactions contemplated by the Loan Documents, the Company additionally agreed to extend the expiration dates of the following
outstanding Common Stock purchase warrants held by the Lender or its affiliated entities until September 30, 2023:
(a)
a warrant to purchase 1,363,636 shares of Common Stock issued on June 30, 2020, that was initially disclosed on the Company’s Current
Report on Form 8-K filed with the SEC on June 30, 2020;
(b)
a warrant to purchase 166,667 shares of Common Stock issued on November 29, 2018, that was initially disclosed on the Company’s
Current Report on Form 8-K filed with the SEC on November 30, 2018; and
(c)
a warrant to purchase 530,027 shares of Common Stock issued on November 29, 2018, that was initially disclosed on the Company’s
Current Report on Form 8-K filed with the SEC on November 30, 2018;
(d)
a warrant to purchase 530,028 shares of Common Stock issued on October 27, 2017 that was initially disclosed on the Company’s Current
Report on Form 8-K filed with the SEC on October 27, 2017.